Photo via Unsplash
Deep within the cellular powerhouses of cancer cells lies an electrical secret that may revolutionize how we predict and treat metastatic disease. Cancer cells have an abnormally high mitochondrial membrane potential (ΔΨm), which is associated with enhanced invasive properties in vitro and increased metastases in vivo. This discovery transforms our understanding of how cellular voltage gradients drive cancer’s most dangerous behavior: its ability to spread throughout the body.
A unique observation of cancer cell mitochondrial function is that many epithelial cancer cell types have an unusually high mitochondrial membrane potential (ΔΨm), compared to their normal counterparts. This elevated voltage isn’t just a quirk of cellular dysfunction—it’s a predictive marker of metastatic potential. Researchers discovered that by measuring ΔΨm, they could identify which cancer cells were most likely to break free and colonize distant organs—before those cells showed any other signs of aggression.
Mitochondria maintain this voltage gradient through a sophisticated proton pumping system. As electrons flow through the respiratory chain complexes, protons are pumped across the inner mitochondrial membrane, creating an electrochemical gradient. Cancer cells appear to exploit this system, maintaining hyperpolarized membranes that somehow enhance their ability to invade surrounding tissue and enter the bloodstream. The researchers tested the predictive power of mitochondrial voltage by sorting cancer cells based on their ΔΨm and then implanting them into animal models. The results were striking: cells with higher membrane potentials showed dramatically increased metastatic capacity, forming tumors at distant sites at rates up to 10 times higher than their lower-voltage counterparts.
The Biophysics of a Hyperpolarized Mitochondrion
To appreciate why mitochondrial voltage matters so profoundly to cancer behavior, it helps to understand the machinery generating it. The inner mitochondrial membrane houses five protein complexes collectively known as the oxidative phosphorylation (OXPHOS) system. Complexes I through IV form the electron transport chain, harvesting electrons from NADH and FADH2 and using the energy released to pump protons from the mitochondrial matrix into the intermembrane space. This proton pumping creates the mitochondrial membrane potential—a charge difference across the inner membrane where the matrix side is strongly negative relative to the intermembrane space.
In healthy cells, this potential typically sits between -140 and -160 millivolts. In many aggressive cancer cells, it climbs to -180 millivolts or beyond. That may sound like a modest shift, but the relationship between membrane potential and cellular behavior is nonlinear. Small voltage changes have outsized effects on the activity of voltage-sensitive proteins embedded in the mitochondrial membrane, particularly those involved in calcium handling, reactive oxygen species (ROS) production, and the import of cytoplasmic proteins into the organelle.
One key downstream consequence of hyperpolarization is altered calcium dynamics. The mitochondrial calcium uniporter (MCU) uses the large negative membrane potential as a driving force to sequester calcium inside the organelle. When ΔΨm is elevated, mitochondria pull more calcium from the cytoplasm, reshaping the calcium signals that regulate cell migration, cytoskeletal remodeling, and the activation of matrix metalloproteinases—enzymes that degrade the extracellular matrix and clear a path for invading tumor cells. In this way, an electrical property of the mitochondrion directly feeds into the physical machinery of metastasis.
Elevated ΔΨm also modulates ROS production in ways that promote invasion. At very high membrane potentials, electron flow through Complex III can become partially uncoupled, generating superoxide radicals. At controlled levels, these ROS molecules act as second messengers that activate pro-invasive signaling pathways including HIF-1 alpha (a master regulator of hypoxia response), NF-kB (a central inflammatory and survival transcription factor), and the PI3K/Akt pathway that drives cell motility. The cancer cell has essentially repurposed the normal electrochemical machinery of energy generation into a signaling platform for aggression.
Sorting by Voltage: From Lab Bench to Predictive Oncology
The experimental approach that made these findings concrete relies on voltage-sensitive fluorescent dyes—compounds like JC-1, TMRE, and MitoTracker Red that accumulate preferentially in mitochondria according to the Nernst equation: the more negative the membrane potential, the more dye accumulates. By staining a heterogeneous population of tumor cells and sorting them using flow cytometry based on dye fluorescence intensity, researchers can physically separate high-ΔΨm cells from low-ΔΨm cells and compare their behavior.
When these sorted subpopulations are tested in Matrigel invasion assays—three-dimensional matrix systems that mimic the extracellular environment—high-voltage cells consistently show greater invasive capacity. They extend more filopodia, degrade more matrix, and migrate directionally toward chemoattractant gradients with greater efficiency. When implanted into immunocompromised mouse models via tail-vein injection, high-ΔΨm cells seed the lungs and liver at dramatically higher rates. The ten-fold difference in metastatic colonization reported across multiple cancer types—including breast, lung, and colorectal—suggests this is a broadly conserved relationship, not a quirk of one tumor lineage.
Perhaps most clinically significant is the temporal dimension: mitochondrial voltage predicts future metastatic behavior in cells that are otherwise phenotypically indistinguishable. Two cancer cells plucked from the same tumor, sharing the same genomic mutations and surface protein expression, can have very different ΔΨm values—and the one with higher voltage is far more likely to eventually form a distant metastasis. This means ΔΨm measurement could serve as a functional biomarker for risk stratification, guiding decisions about adjuvant therapy intensity before clinical metastasis appears.
Therapeutic Implications: Targeting the Voltage
If hyperpolarized mitochondria enable metastasis, then selectively depolarizing cancer cell mitochondria becomes a compelling therapeutic strategy. Several classes of compounds already do exactly this, and their anti-metastatic properties are being actively investigated. Mitochondria-targeted cationic molecules—so-called mitocans—accumulate in the inner mitochondrial membrane driven by the same Nernst potential that concentrates fluorescent dyes. Because cancer cells have higher ΔΨm than normal cells, these agents accumulate preferentially in tumor mitochondria, potentially achieving selective toxicity.
Among the most studied is a family of triphenylphosphonium (TPP+)-conjugated compounds that can be loaded with cytotoxic payloads or mitochondrial uncouplers. MitoQ, a TPP+-linked antioxidant originally developed to scavenge mitochondrial ROS, has shown secondary effects on membrane potential. More directly, compounds like FCCP are potent uncouplers that collapse the proton gradient—but their lack of tumor selectivity limits clinical utility. The challenge for the field is engineering agents with sufficient tumor selectivity to exploit the ΔΨm differential therapeutically.
A parallel approach targets the proteins responsible for maintaining elevated ΔΨm. Inhibitors of Complex I—such as metformin and IACS-010759—reduce proton pumping and lower membrane potential. Metformin’s epidemiological association with reduced cancer incidence and metastasis in diabetic patients has long puzzled oncologists; its effects on mitochondrial membrane potential offer a mechanistic explanation worth investigating further in prospective clinical trials.
Beyond direct pharmacology, the ΔΨm framework opens a diagnostic window. PET tracers that respond to mitochondrial membrane potential—most notably the rhodamine derivative 99mTc-sestamibi, used in cardiac imaging—are already FDA-approved and could theoretically be repurposed to image high-ΔΨm tumor subpopulations in vivo. The voltage of a cell’s mitochondria, once an obscure detail of bioenergetics textbooks, is emerging as one of oncology’s most actionable electrical signals—a measurable, targetable marker sitting at the intersection of metabolism, motility, and the electrical logic of life itself.
Sources and Further Reading
- Bonora, M. et al. (2012). Mitochondrial membrane potential. Methods in Enzymology, 542.
- Liberti, M.V. & Locasale, J.W. (2016). The Warburg effect: how does it benefit cancer cells? Trends in Biochemical Sciences, 41(3).
- Levin, M. (2021). Bioelectric signaling: Reprogrammable circuits underlying embryogenesis, regeneration, and cancer. Cell, 184(8).